$2.24T
Total marketcap
$73.77B
Total volume
BTC 56.30%     ETH 8.99%
Dominance
Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ) XVIPF Stock

$29.00   0.000000%
Add to favorites
Market Cap
$913.52M
LOW - HIGH [24H]
$19.15 - $19.33
VOLUME [24H]
$200.00
P/E Ratio
120.83
Earnings per share
$0.24
ISIN
SE0004840718
Price   Prediction

Xvivo Perfusion AB (publ) Price Chart

Sorry, that's all we've gotfor now...

Xvivo Perfusion AB (publ) XVIPF Financial and Trading Overview

Xvivo Perfusion AB (publ) stock price 29 USD
Previous Close 29 USD
Open 19.33 USD
Bid 25.54 USD x 10000
Ask 27.06 USD x 10000
Day's Range 19.15 - 19.33 USD
52 Week Range 16.98 - 32.9 USD
Volume 200 USD
Avg. Volume 8 USD
Market Cap 603.21M USD
Beta (5Y Monthly) 1.436
PE Ratio (TTM) 76.6
EPS (TTM) 0.24 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

XVIPF Valuation Measures

Enterprise Value N/A
Trailing P/E 76.6
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 0.2881042
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Xvivo Perfusion AB (publ) Stock Price History

Beta (5Y Monthly) 1.436
52-Week Change -11.85%
S&P500 52-Week Change 22.66%
52 Week High 32.9 USD
52 Week Low 16.98 USD
50-Day Moving Average 26.05 USD
200-Day Moving Average 21.54 USD

XVIPF Share Statistics

Avg. Volume (3 month) 8 USD
Avg. Daily Volume (10-Days) 11 USD
Shares Outstanding 31.5M
Float 25.13M
Short Ratio N/A
% Held by Insiders 7.84%
% Held by Institutions 60.47%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) March 31, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 8.85%
Operating Margin (ttm) 0%
Gross Margin 73.11%
EBITDA Margin 16.44%

Management Effectiveness

Return on Assets (ttm) 2.61%
Return on Equity (ttm) 3.46%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) 10.19%
Gross Profit (ttm) N/A
EBITDA 137.23M USD
Net Income Avi to Common (ttm) N/A
Diluted EPS (ttm) 0.25
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) N/A
Total Cash Per Share (mrq) N/A
Total Debt (mrq) N/A
Total Debt/Equity (mrq) 5.66 USD
Current Ratio (mrq) 4.519
Book Value Per Share (mrq) 66.469

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) -86488496 USD

Profile of Xvivo Perfusion AB (publ)

Country United States
State N/A
City Mölndal
Address Gemenskapens gata 9
ZIP 431 53
Phone 46 3 17 88 21 50
Website https://www.xvivogroup.com
Industry Medical Devices
Sector(s) Healthcare
Full Time Employees 199

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Q&A For Xvivo Perfusion AB (publ) Stock

What is a current XVIPF stock price?

Xvivo Perfusion AB (publ) XVIPF stock price today per share is 29 USD.

How to purchase Xvivo Perfusion AB (publ) stock?

You can buy XVIPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Xvivo Perfusion AB (publ)?

The stock symbol or ticker of Xvivo Perfusion AB (publ) is XVIPF.

Which industry does the Xvivo Perfusion AB (publ) company belong to?

The Xvivo Perfusion AB (publ) industry is Medical Devices.

How many shares does Xvivo Perfusion AB (publ) have in circulation?

The max supply of Xvivo Perfusion AB (publ) shares is 31.5M.

What is Xvivo Perfusion AB (publ) Price to Earnings Ratio (PE Ratio)?

Xvivo Perfusion AB (publ) PE Ratio is 120.83792000 now.

What was Xvivo Perfusion AB (publ) earnings per share over the trailing 12 months (TTM)?

Xvivo Perfusion AB (publ) EPS is 0.24 USD over the trailing 12 months.

Which sector does the Xvivo Perfusion AB (publ) company belong to?

The Xvivo Perfusion AB (publ) sector is Healthcare.

Select currency